New drug targets 'Undruggable' cancer mutation in first human trial
NCT ID NCT05533463
Summary
This is a first-in-human study to test the safety and side effects of a new drug called HRS-4642. It is for adults with advanced solid tumors that have a specific genetic change called a KRAS G12D mutation. The main goals are to find a safe dose and see how the body processes the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED KRAS G12D MUTANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
Conditions
Explore the condition pages connected to this study.